A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function
Status:
Completed
Trial end date:
2019-08-07
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess the amount of study drug that reaches the
bloodstream and the time it takes for the body to get rid of it when given to participants
with renal (kidney) impairment compared to healthy participants. The study will last up to 9
days, excluding screening.